|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00001482 |
|
Date of registration:
|
03/11/1999 |
|
Primary sponsor: |
|
|
Public title:
|
New Drugs in the Treatment of Mood Disorders
|
|
Scientific title:
|
Evaluation of Lamotrigine (Lamictal® (Registered Trademark)) Monotherapy and Gabapentin (Neurontin® (Registered Trademark)) Monotherapy in the Treatment of Mood Disorders |
|
Date of first enrolment:
|
May 1995 |
|
Target sample size:
|
60 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00001482 |
|
Study type:
|
Interventional |
|
Study design:
|
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Patients between the ages of 18 and 75 who satisfy DSM-III-R criteria for mood disorders,
are refractory to at least two conventional treatments, and are inpatients or outpatients
at the NIMH are invited to participate provided that the following criteria are fulfilled:
Subjects having serious medical illness (or meeting current psychoactive substance
dependence will be excluded from entry.)
Age minimum:
N/A
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Anxiety Disorder
|
|
Mood Disorder
|
|
Psychotic Disorder
|
|
Intervention(s)
|
|
Drug: Gabapentin (Neurontin® (Registered Trademark))
|
|
Drug: Lamotrigine (Lamictal® (Registered Trademark)
|
|
Secondary ID(s)
|
|
95-M-0115
|
|
950115
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|